Enveric Biosciences, Inc.
ENVB
$1.27
$0.010.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.70% | -25.99% | -54.60% | -53.07% | -33.44% |
| Depreciation & Amortization | -2.86% | -1.89% | -1.76% | -1.42% | -0.64% |
| Other Operating Expenses | -129.57% | -129.57% | -- | -- | -- |
| Total Operating Expenses | -33.58% | -41.44% | -53.13% | -51.56% | -29.77% |
| Operating Income | 33.58% | 41.44% | 53.13% | 51.56% | 29.77% |
| Income Before Tax | 38.19% | 44.59% | 59.06% | 55.38% | 25.21% |
| Income Tax Expenses | -76.47% | -69.20% | 101.62% | 102.06% | 102.06% |
| Earnings from Continuing Operations | 38.27% | 44.63% | 56.26% | 52.26% | 19.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.27% | 44.63% | 56.26% | 52.26% | 19.08% |
| EBIT | 33.58% | 41.44% | 53.13% | 51.56% | 29.77% |
| EBITDA | 34.34% | 42.28% | 54.09% | 52.40% | 30.28% |
| EPS Basic | 86.25% | 82.57% | 76.04% | 66.71% | 39.72% |
| Normalized Basic EPS | 86.19% | 82.39% | 67.02% | 54.03% | 15.31% |
| EPS Diluted | 86.25% | 82.57% | 76.04% | 66.71% | 39.72% |
| Normalized Diluted EPS | 86.19% | 82.39% | 67.02% | 54.03% | 15.31% |
| Average Basic Shares Outstanding | 403.10% | 249.19% | 167.64% | 99.05% | 50.73% |
| Average Diluted Shares Outstanding | 403.10% | 249.19% | 167.64% | 99.05% | 50.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |